Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events (TRACE-BRIDGE): A Multicenter, Randomized, Open-Label, Three-Arm, Blinded-Endpoint Phase III Trial

NCT07748039 is registered in ClinicalTrials.gov with Yongjun Wang as lead sponsor.

NCT NCT07748039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07748039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events (TRACE-BRIDGE): A Multicenter, Randomized, Open-Label, Three-Arm, Blinded-Endpoint Phase III Trial
Lead sponsor
Yongjun Wang
Phase
Phase 3
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
August 1, 2029
Enrollment
1,440 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke, anterior circulation brain infarction, large vessel occlusion